Market revenue in 2023 | USD 412.6 million |
Market revenue in 2030 | USD 599.4 million |
Growth rate | 5.5% (CAGR from 2023 to 2030) |
Largest segment | Cmos & cdmos |
Fastest growing segment | CMOs & CDMOS |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biopharmaceutical Companies, CMOs & CDMOS, Academic And Research Organizations |
Key market players worldwide | Danone SA, Roche Holding AG ADR, Koninklijke DSM NV, Lonza Group Ltd, Novonesis AS ADR, Biocon, BioVectra, TerraVia - Assets, BiOZEEN |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbial fermentation technology market will help companies and investors design strategic landscapes.
Cmos & cdmos was the largest segment with a revenue share of 41.93% in 2023. Horizon Databook has segmented the Italy microbial fermentation technology market based on biopharmaceutical companies, cmos & cdmos, academic and research organizations covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing demand and continuous development of biosimilars & biopharmaceuticals are boosting the implementation of microbial fermentation technologies in Italy. The Italian biotechnology industry has witnessed significant growth due to tremendous advancements in biomanufacturing and industrial research.
The country hosts several biotechnology & biopharmaceutical hotspots and is home to several key players in the market. For instance, Milan is the hub of biotechnology sector in Italy, housing approximately 35% of all biotechnology companies. Furthermore, business developments in the country are making it a cash-generating market for microbial fermentation technology and driving the market.
nagni, the Italy facility of Catalent Biologics, was completely acquired from Bristol Myers Squibb in 2020 to increase the manufacturing of biologics in Europe. Considering further expansion plans and the increasing demand for such products, the market is projected to grow during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy microbial fermentation technology market , including forecasts for subscribers. This country databook contains high-level insights into Italy microbial fermentation technology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account